TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25269885
Drug: Saxagliptin/metformin XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin/metformin XR 5/500 mg FDC tablet
Study: 25269885
Drug: Saxagliptin/metformin XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin/metformin XR 5/1,000 mg FDC tablet
Study: 25269885
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of saxagliptin and metformin XR
Study: 20195158
Drug: Slow-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release melatonin (6 mg) given at bedtime for 4 weeks
Study: 18343246
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg (titrated to 8 mg if needed)
Study: 18343246
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (titrated to 100 mg if needed)
Study: 30409962
Drug: P53 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P53 inhibitor (1 μM bpV)
Study: 20028464
Drug: No-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment group (waitlist)
Study: 18556085
Drug: Modified Yale
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Yale insulin infusion protocol (MY group)
Study: 15821487
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists (GnRH-A)
Study: 10487267
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg orally twice daily
Study: 10487267
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg orally three times daily
Study: 9081556
Drug: Conditioned stimulus
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioned stimulus plus 10 mg of cyclophosphamide
Study: 1936485
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 tabs/d, i.e. 1,700 mg/d)
Study: 6217028
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive (30-40-30 micrograms EE and 50-75-125 micrograms levonorgestrel)
Study: 6217028
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose oral contraceptive (30 micrograms EE and 150 micrograms desogestrel)
Study: 6217028
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose oral contraceptive
Study: 27052428
Drug: Albuvirtide (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuvirtide (320 mg) and Lopinavir/Ritonavir (400/100 mg)
Study: 27052428
Drug: Lopinavir/Ritonavir (400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (400/100 mg)
Study: 23855176
Drug: Oral Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Midazolam 0.5 mg/kg
Study: 23855176
Drug: Oral Diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Diazepam 0.5 mg/kg
Study: 23855176
Drug: Intravenous Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Midazolam 0.06 mg/kg
Study: 21394570
Drug: Pharmacotherapy follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy follow-up (PF)
Study: 12520634
Drug: Capecitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,000 mg/m2 twice daily on days 1 to 14) plus IV irinotecan (250 mg/m2 on day 1 every 21 days)
Study: 7521118
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate in combination with UFT (group B)
Study: 4524016
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride application once a year
Study: 4524016
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride application twice a year with 6 month interval
Study: 4524016
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical fluoride application (control group)
Study: 23594263
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human C1 inhibitor (rhC1INH) administered at a dosing scheme of 50 U kg(‐1) up to 84 kg, with a fixed dose of 4200 U above 84 kg.
Study: 23594263
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human C1 inhibitor (rhC1INH) in symptomatic HAE patients.
Study: 23594263
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human C1 inhibitor (rhC1INH) in healthy volunteers.
Study: 21615875
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose CTPI (19.62 mSv)
Study: 21615875
Drug: Median dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median dose CTPI (12.61 mSv)
Study: 21615875
Drug: Low-dose CTPI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CTPI (7.01 mSv)
Study: 21615875
Drug: Low-dose CTPI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CTPI in patients with HCC
Study: 17109592
Drug: Twice-daily NPH/regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily NPH/regular insulin
Study: 17109592
Drug: Once-daily glargine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily glargine insulin
Study: 7520297
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution with low molecular weight hydroxyethyl starch (HS-HES)
Study: 7520297
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight hydroxyethyl starch solution (LMW-HES)
Study: 2837106
Drug: terbutaline (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline (7 micrograms/kg, subcutaneous injection)
Study: 22585541
Drug: loose snus
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: loose snus (27.1 mg nicotine)
Study: 22585541
Drug: pouched snus
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pouched snus (14.7 mg nicotine)
Study: 22585541
Drug: loose snus
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: loose snus (10.8 mg nicotine)
Study: 22585541
Drug: nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nicotine gum (4.2 mg nicotine)
Study: 22585541
Drug: pouched snus
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pouched snus (1 g portion, ~11 mg nicotine)
Study: 21577030
Drug: 10-week twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-week twice weekly exercise group program (gymnastics, movement games, relaxation, walking, jogging)
Study: 8904260
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diazepam and propofol
Study: 2276106
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone call intervention in addition to usual care
Study: 533286
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical applications of a steroid and nonsteroid anti-inflammatory agent
Study: 533286
Drug: Nonsteroid anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroid anti-inflammatory agent
Study: 533286
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of steroid and nonsteroid agents
Study: 533286
Drug: Steroid or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid or nonsteroid agent alone
Study: 533286
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of agents
Study: 19088698
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.25 microg kg(‐1) hr(‐1))
Study: 19088698
Drug: Midazolam infusion
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam infusion (25 microg kg(‐1) hr(‐1))
Study: 17604045
Drug: Selective invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective invasive (SI) treatment strategy
Study: 15998467
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (24 hours bed rest and ample fluid intake)
Study: 7630912
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care regime using saline rinses
Study: 7630912
Drug: Oral assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral assessment guide and protocol
Study: 2905069
Drug: Temazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (10 mg for one night)
Study: 20386078
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 2 weeks
Study: 18377693
Drug: Co-enzyme Q10
Normalized name: Thrifty White Co-Enzyme Q10 100mg Capsule
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-enzyme Q10 (100 mg), Riboflavin (10 mg), Niacin (50 mg) along with Tamoxifen (10 mg twice per day)
Study: 20356911
Drug: Intravenous n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous n-3 polyunsaturated fatty acids (PUFA) infusion (3.9 g)
Study: 20356911
Drug: Intravenous n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous n-3 PUFA infusion
Study: 11403364
Drug: Amlodipine (5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5/10 mg) +/‐ Perindopril (4/8 mg)
Study: 11403364
Drug: Atenolol (50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50/100 mg) +/‐ Bendroflumethiazide (1.25/2.5 mg) + K+
Study: 9755995
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg at bedtime (maintenance group)
Study: 9755995
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active therapy (antibiotic group)
Study: 9755995
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg at bedtime (intent to treat analysis)
Study: 9755995
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active therapy (intent to treat analysis)
Study: 3283093
Drug: Amoxycillin sachets
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin sachets 3g twice daily for three days
Study: 3283093
Drug: Amoxycillin capsules
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin capsules 500 mg three times daily for seven days
Study: 3283093
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course high dose therapy
Study: 29696564
Drug: M2000 (β-D-mannuronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2000 (β-D-mannuronic acid) administered at a dose of two capsules (500 mg) per day orally for 12 weeks
Study: 23200102
Drug: GNbAC1 0.0025,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNbAC1 0.0025, 0.025, 0.15, 0.6, 2, or 6 mg/kg
Study: 23200102
Drug: GNbAC1 2
Normalized name: Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNbAC1 2 and 6 mg/kg
Study: 17957907
Drug: Ginger (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (0.5 gm capsule, twice daily)
Study: 17957907
Drug: Dimenhydrinate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate (50 mg capsule, twice daily)
Study: 11468200
Drug: Eptifibatide (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (180 microgram/kg bolus and 2.0 microgram/kg per minute infusion for 72 hours)
Study: 21903957
Drug: Isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone soy protein (ISP) supplementation (25 g daily for 2.7 years)
Study: 21903957
Drug: Isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone soy protein (ISP) supplementation (25 g daily for 2.7 years) in women <5 years postmenopausal
Study: 19086328
Drug: Panitumumab monotherapy
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab monotherapy
Study: 10450292
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (rich in fruits, vegetables, and low-fat dairy products)
Study: 10450292
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (in participants with hypertension)
Study: 10450292
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (in participants without hypertension)
Study: 8738446
Drug: Forceful epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forceful epidural corticosteroid injections (125 mg prednisolone acetate + 40 ml saline)
Study: 8738446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (125 mg prednisolone acetate alone)
Study: 8738446
Drug: Forceful epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forceful epidural corticosteroid injections
Study: 2018658
Drug: STH +
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: STH + CP (creatine phosphate 10.0 mmol/l)
Study: 31607387
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (loading dose of 500 mg and continuous infusion of 250 mg h‐1)
Study: 25365652
Drug: Sandwich Bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich Bone Augmentation (SBA)
Study: 24707200
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of DTM and NSAID
Study: 22960162
Drug: Motivational coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational coaching at home and by phone with a health educator, mailed educational materials, and weekly text messages for 6 months.
Study: 20071900
Drug: Koryo Hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Koryo Hand Therapy (KHT), applied three times a week for 8 weeks
Study: 17395516
Drug: Weekly medical
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly medical support through SMS based upon weekly review of glucose values
Study: 17395516
Drug: No SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No SMS (self‐monitored blood glucose values downloaded weekly without SMS)
Study: 10102965
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy with ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d.
Study: 10102965
Drug: 10-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day therapy with ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d.
Study: 2185825
Drug: Maize starch
Normalized name: Maize starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize starch paste with 240 g amylose/kg (S24)
Study: 2185825
Drug: Maize starch
Normalized name: Maize starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize starch paste with 500 g amylose/kg (S50)
Study: 6109469
Drug: Midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.15 mg/kg body weight) injected over 60 seconds
Study: 6109469
Drug: Midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.15 mg/kg body weight) injected over 15 seconds
Study: 29029135
Drug: Simeprevir 150mg
Normalized name: SIMEPREVIR 150MG CAP
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 150mg once daily for 7 days
Study: 29029135
Drug: Dolutegravir 50mg
Normalized name: DOLUTEGRAVIR 50MG TAB
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir 50mg once daily for 7 days
Study: 29029135
Drug: Simeprevir 150mg
Normalized name: SIMEPREVIR 150MG CAP
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 150mg once daily plus Dolutegravir 50mg once daily for 7 days
Study: 22708417
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training (PT) combined with standard pharmacotherapy and respiratory training
Study: 15974417
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine (10 mg morphine hydrochloride with Intrasite Gel)
Study: 15974417
Drug: Placebo (Intrasite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Intrasite Gel with placebo)
Study: 12902209
Drug: Three drugs
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drugs FDC
Study: 12902209
Drug: Four drugs
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four drugs FDC
Study: 6094443
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g im or iv on call to the operating room)
Study: 6094443
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g im or iv on call to the operating room, followed by 2 g intravenously at 6 hourly intervals for up to 24 h)
Study: 2948731
Drug: 5 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/m2 5'‐dFUrd
Study: 2948731
Drug: 3 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/m2 5'‐dFUrd
Study: 29733038
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (control group).
Study: 27718781
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg per day, 4-weeks-on, 2-weeks-off for 1 year)
Study: 18551108
Drug: Daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exercise (EX)
Study: 14556925
Drug: Glufosfamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glufosfamide (5 g/m²) administered via 1-hour intravenous infusion every 3 weeks
Study: 10759342
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus Pindolol (FLX + PIN)
Study: 10759342
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus Placebo (FLX + PLA)
Study: 8636433
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no IL-2 therapy)
Study: 6731261
Drug: Trimazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin (2 mg/kg)
Study: 17685870
Drug: Local therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapies (anti-vascular endothelial growth factor strategies, anti-inflammatory agents, gene therapy, and stem cell therapy)
Study: 17685870
Drug: Systemic drug
Normalized name: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic drug administration (protein kinase C inhibitors and somatostatin analogs)
Study: 17685870
Drug: Intravitreal delivery
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal delivery of local therapies
Study: 12066727
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine solution 3 mg kg(‐1) (n=20)
Study: 12066727
Drug: mepivacaine 5
Normalized name: mepivacaine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepivacaine 5 mg kg(‐1) (n=22)
Study: 12066727
Drug: lidocaine 3
Normalized name: Lidocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 3 mg kg(‐1) (n=20)
Study: 8872694
Drug: Oral glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycopyrrolate
Study: 31414980
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy with <5 g long chain triglyceride fat per day recommended by dietitians in Australia/New Zealand, UK, and Ireland
Study: 31414980
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy duration of 4 weeks or 6 weeks
Study: 28577680
Drug: Udenafil 87.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 87.5 mg bid
Study: 28577680
Drug: Udenafil (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil (various doses: 37.5, 87.5, 125 mg daily, 37.5 and 87.5 mg bid)
Study: 24127442
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (no GO)
Study: 20852004
Drug: Pantoprazole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (both doses)
Study: 17006117
Drug: Chlorhexidine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.2% wt/vol oral rinse